A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Venglustat (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Pharmacokinetics
- Sponsors Sanofi Genzyme
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 20 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.
- 20 Feb 2019 Status changed from recruiting to active, no longer recruiting.